Barclays Q2 Review on Pfizer (PFE): Will There Be Growth in 2013?
Tweet
Share
E-mailGet Alerts PFE Hot Sheet
Price: $26.79 -0.04%
Rating Summary:
14 Buy, 20 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
14 Buy, 20 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Barclays maintains an 'Equalweight' on Pfizer (NYSE: PFE) price target of $22.00.
Analyst, C. Anthony Butler, noted that PFE topped Q2 estimates by $0.08 on stronger-than-expected revenues...with emerging markets giving a big push. Looking into 2013, Butler sees major product launches, but a return of biopharma growth may have to wait. He cites a possible 3-month delay in the approval of tofacitinib and he doesn't feel ORAL-START will persuade physicians to bypass methrotrexate. Eliquis should get approval in December and core drivers like Prevnar 13 and Lyrica may not completely offset expiration pressures in 2012.
Separately, Butler doesn't see the company spinning-off or selling more established products, however, dacomitinib and the meningitis B vaccine should sustain pipeline interest.
For an analyst ratings summary and ratings history on Pfizer click here. For more ratings news on Pfizer click here.
Shares of Pfizer closed at $24.04 yesterday.
Analyst, C. Anthony Butler, noted that PFE topped Q2 estimates by $0.08 on stronger-than-expected revenues...with emerging markets giving a big push. Looking into 2013, Butler sees major product launches, but a return of biopharma growth may have to wait. He cites a possible 3-month delay in the approval of tofacitinib and he doesn't feel ORAL-START will persuade physicians to bypass methrotrexate. Eliquis should get approval in December and core drivers like Prevnar 13 and Lyrica may not completely offset expiration pressures in 2012.
Separately, Butler doesn't see the company spinning-off or selling more established products, however, dacomitinib and the meningitis B vaccine should sustain pipeline interest.
For an analyst ratings summary and ratings history on Pfizer click here. For more ratings news on Pfizer click here.
Shares of Pfizer closed at $24.04 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Piper Sandler Reiterates Overweight Rating on Estee Lauder (EL), 'F4Q26 Preview'
- Jefferies on Five Below (FIVE): 'Our latest channel checks reinforce our view that FIVE's momentum extends well beyond viral Squish trends'
- Powell Industries (POWL) PT Lowered to $235 at Cantor Fitzgerald
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS ViewRelated Entities
BarclaysSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
